Eisai Appoints CEO’s 34-Year-Old Son to Lead Global Alzheimer Drug Program

Activist Fights Tick Up, Along With Settlements to Head Them Off

NATO Summit, Ukraine’s Arms Plan: Your Sunday US Briefing

How a Japanese Drugmaker Clinched Win Over Alzheimer’s

Eisai Alzheimer's Drug Gets Full US Approval, Widening Access to the Therapy

Eisai, Biogen Clinch FDA Advisers’ Support for Alzheimer’s Drug

Drug Companies Are Minting Billions on Unproven Treatments With FDA Shortcut